Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B by Tran, Thi A. et al.
Lipopolysaccharide and Tumor Necrosis Factor Regulate
Parkin Expression via Nuclear Factor-Kappa B
Thi A. Tran
1, Andrew D. Nguyen
2, Jianjun Chang
2, Matthew S. Goldberg
3,4, Jae-Kyung Lee
2,M a l u ´ G.
Tansey
1,2*
1Departments of Physiology, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, 2Department of Physiology, Emory University
School of Medicine, Atlanta, Georgia, United States of America, 3Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, Texas, United
States of America, 4Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
Abstract
Inflammation and oxidative stress have been implicated in the pathophysiology of Parkinson’s disease (PD) and inhibition of
microglial activation attenuates degeneration of dopaminergic (DA) neurons in animal models of PD. Loss-of-function
mutations in the parkin gene, which encodes an E3 ubiquitin ligase, cause autosomal recessive parkinsonism. While most
studies on Parkin have focused on its function in neurons, here we demonstrate that Parkin mRNA and protein is detectable
in brain-resident microglia and peripheral macrophages. Using pharmacologic and genetic approaches, we found that
Parkin levels are regulated by inflammatory signaling. Specifically, exposure to LPS or Tumor Necrosis Factor (TNF) induced a
transient and dose-dependent decrease in Parkin mRNA and protein in microglia, macrophages and neuronal cells
blockable by inhibitors of Nuclear Factor-Kappa B (NF-kB) signaling and not observed in MyD88-null cells. Moreover, using
luciferase reporter assays, we identified an NF-kB response element in the mouse parkin promoter responsible for mediating
the transcriptional repression, which was abrogated when the consensus sequence was mutated. Functionally, activated
macrophages from Parkin-null mice displayed increased levels of TNF, IL-1b, and iNOS mRNA compared to wild type
macrophages but no difference in levels of Nrf2, HO-1, or NQO1. One implication of our findings is that chronic
inflammatory conditions may reduce Parkin levels and phenocopy parkin loss-of-function mutations, thereby increasing the
vulnerability for degeneration of the nigrostriatal pathway and development of PD.
Citation: Tran TA, Nguyen AD, Chang J, Goldberg MS, Lee J-K, et al. (2011) Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear
Factor-Kappa B. PLoS ONE 6(8): e23660. doi:10.1371/journal.pone.0023660
Editor: Mark P. Mattson, National Institute on Aging Intramural Research Program, United States of America
Received April 15, 2011; Accepted July 22, 2011; Published August 17, 2011
Copyright:  2011 Tran et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from NIH-NINDS 5R01NS049433 and The Michael J. Fox Foundation for Parkinson’s Research. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: malu.tansey@emory.edu
Introduction
Parkinson’s disease (PD) is a progressive, neurodegenerative
disorder affecting approximately 1–2% of the adult population
over 65 years of age [1]. The majority of PD cases are thought be
sporadic, meaning the disease arises in individuals without genetic
susceptibility for PD [2]. Several lines of evidence implicate
neuroinflammation as a contributing factor in PD pathogenesis
[3,4,5,6]. Notably, PET imaging studies of PD patients show
increased neuroinflammation as evidenced by microglial activa-
tion in brain regions most affected by PD compared to healthy,
age-matched controls [7]. Neuroinflammation is largely charac-
terized by activation of microglia [8]. These monocyte-derived
brain resident macrophages are central players in innate immune
responses in the brain. Environmental toxins, genetic mutations,
traumatic brain injury, and infection are among the factors known
to activate microglia [9,10].
Mutations in the parkin gene (PARK2), which encode for an E3
ubiquitin ligase, are the leading cause of early-onset, autosomal
recessive parkinsonism [11,12,13]. Parkin levels in neurons are
associated with protection from cellular stress and cell cycle
regulation. Treatment of SH-SY5Y cells with rotenone, glutamate
or kainic acid induced increases in Parkin protein and mRNA
within 3 to 8 hours of exposure [14]. Additionally, Parkin
expression was recently reported to increase with mitochondrial
or ER stress as mediated by ATF4 [15]. In regards to cell cycle
regulation, increased levels of Parkin were associated with cell
cycle arrest in neuroblastoma cells, which is transcriptionally
mediated by N-myc [16]. These findings demonstrate that Parkin
levels are transcriptionally regulated in neurons to control
development and cellular stress. However, whether Parkin
expression is regulated in microglia and whether levels are
affected by cellular functioning is still unknown.
We recently demonstrated that the nigrostriatal pathway of
Parkin-null mice displayed increased vulnerability to inflamma-
tion-induced degeneration when exposed to chronic systemic
lipopolysaccharide (LPS) [17]. This finding demonstrated that
inflammatory activation not only in the central nervous system
(CNS) but also in the periphery may influence neuronal survival in
the CNS. Therefore, we posit that gene-environment interactions
between inflammatory pathways in glial cells, and gene products
such as Parkin, are critical for protection against cellular stress
which may contribute to the development of PD. In support of this
idea, we report that Parkin levels in microglia and macrophages
are dynamically regulated at the transcriptional level in an NF-kB-
dependent manner.
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Animal Studies
Experimental procedures involving use of animal tissue were
performed in accordance with the NIH Guidelines for Animal
Care and Use and approved by the Institutional Animal Care and
Use Committee at The University of Texas Southwestern Medical
Center in Dallas, Texas (Protocol No. 0949-06-11-1 and 0949-04-
05-1) and Emory University School of Medicine in Atlanta,
Georgia (Protocol No. 208-2009). Animals were housed in
climate-controlled pathogen-free facilities staffed with certified
veterinarians, maintained on a twelve-hour lights-on/off cycle,
and allowed food and water ad libitum. Parkin-null mice were
generated as previously described [18] and have been backcrossed
to strain C57BL/6 for over ten generations. TNF-null (B6;129S6-
Tnftm1Gkl/J; stock number 003008) mice on a C57BL/6
background strain along with wild type mice as non-transgenic
controls were obtained from Jackson Labs (Bar Harbor, ME).
Reagents
Lipopolysaccharide (LPS) E.coli strain 0111:B4 (Catalog #
L4391) was purchased from Sigma-Aldrich (St. Louis, MO). SN50
NF-kB peptide (Cat#481480) was purchased from Calbiochem.
Tumor necrosis alpha (TNF) was purchased from R&D Systems
(Minneapolis, MN). CDDO-Im was a kind gift from Dr. Michael
Sporn (Dartmouth University).
Cell Culture
The murine BV2 microglia cell line was generated by Dr.
Bistoni and colleagues by infecting primary microglial cell cultures
with the v-raf/v-myc oncogene carrying retrovirus J2 [19]. BV2
microglial cells were cultured in DMEM/F12 (Sigma-Aldrich)
supplemented with 5% heat-inactivated fetal bovine serum (FBS),
1% penicillin/streptomycin, and 1% L-glutamine all purchased
from Sigma-Aldrich. Cells were serially passaged when they
reached 70% confluence. The murine clonal hybrid cell line
MN9D was developed by A. Heller and colleagues by somatic cell
fusion of rostral mesencephalic tegmentum from E14 mice and the
murine neuroblastoma cell line N18TG2 [20]. MN9D cells were
grown in DMEM (Sigma-Aldrich) supplemented with 10% Fetal
Clone III (Hyclone) and 1% penicillin/streptomycin. Cells were
serially passaged when they reached 70% confluence. To induce
terminal neuron-like differentiation of MN9D cells, cells were
incubated with 5 mM valproic acid (Sigma-Aldrich) in N2
(Invitrogen)-supplemented serum-free DMEM (Sigma-Aldrich)
for 3 days.
Culture of Primary Microglia
Primary microglia were harvested from postnatal day 2–4 (P2–
P4) wild type C57BL/6 or Parkin-null mouse pups using
previously published protocols [21]. Briefly, brain tissue was
removed, finely minced with a razor, incubated in 0.25% trypsin
(Sigma-Aldrich) containing 0.5% v/v DNaseI (Invitrogen) for
20 minutes at 37uC. After neutralization with serum-containing
DMEM/F12 growth medium, cells were centrifuged, passed
through a 40 mM filter (BD Falcon), and plated in cell culture
flasks. Cells were fed every 3–4 days with fresh media (DMEM/
F12 supplemented with 20% heat-inactivated FBS (Sigma-
Aldrich), 1% penicillin-streptomycin, and 1% L-glutamine (Sig-
ma-Aldrich)). After 14–18 days in vitro, microglia were isolated
from cultures by mechanical agitation (150 rpm, 40 min at 37uC).
The cultures were checked for purity and found to contain .95%
microglia as determined by cell-type specific expression of CD68
and less than 5% astrocytes as determined by GFAP immunore-
activity.
Culture of Primary Macrophages
Murine peritoneal macrophages were obtained by eliciting an
acute peripheral inflammatory reaction with an intraperitoneal
(i.p.) injection of thioglycolate [22]. Briefly, adult mice were given
an i.p. injection of 3% Brewer’s yeast thioglycolate in normal
saline. Three days later peritoneal exudates were recovered,
pelleted and resuspended in culture media (high-glucose DMEM
supplemented with 10% FBS from Atlanta Biologicals (Norcross,
GA), 1% penicillin/streptomycin, and 1% L-glutamine (Sigma-
Aldrich). Six hours after the initial plating, cells were washed twice
with PBS to remove non-adherent cells and growth medium was
replenished to the homogeneous population of adherent macro-
phages.
Immunoblot Analysis
Cells were treated as indicated and washed once with PBS
before harvesting with 26Laemmli buffer. Total cell lysates were
stored at 280uC until use. Cell lysate proteins were resolved on
10% SDS-PAGE gels (Bio-Rad, Hercules, CA) and transferred
onto PDVF membranes (Millipore, Billerica, MA). Immunoblot-
ting was performed using anti-Parkin (PARK8) (Covance,
Princeton, NJ) and anti-alpha tubulin (Calbiochem, Gibbstown,
NJ) antibodies. Membranes were stripped with 0.2 M glycine, 1%
SDS and 0.1% Tween-20, pH 2.2 and re-probed as necessary.
Quantitative Real-Time Polymerase Chain Reaction
(QPCR)
QPCR was performed as previously described [23]. Briefly,
total RNA was isolated from cells in culture using Tri-Reagent
(Molecular Research Center Inc., Cincinnati, OH) or the RNeasy
isolation kit (Qiagen, Valencia, CA), treated with DNaseI, and
reverse transcribed using Superscript II RNase H- reverse
transcriptase (Invitrogen). QPCR was performed using SYBR
Green in 384-well format using an ABI Prism 7900HT Fast
Detection System (Applied Biosystems, Foster City, CA). Oligo-
nucleotide primers for QPCR were obtained from Integrated
DNA Technologies (Coralville, IA). All mouse primer sequences
(available upon request) were validated and used for gene
amplification. Levels of mRNA expression were normalized to
those of the mouse house-keeping genes cyclophilin B, GAPDH
and/or b-actin. Values represent the mean value of triplicate
samples +/2 SEM. Data are representative of at least two
independent experiments.
Generation of Parkin Reporter Plasmids
Sequences containing the 59-flanking region of the mouse parkin
gene were amplified by PCR with the Phusion DNA polymerase
kit (New England Biolabs, Ipswich, MA). Mouse genomic DNA
isolated from a C57BL/6 mouse was used as the template. The
forward and reverse primers used for amplification of Parkin #1
(see Fig. 4A) are GAGATGGTGTGACAAGGGGAATGA-
GAAG and CCCCTGTCGCTTAGCAACCACTTC, respec-
tively. The forward and reverse primers used for amplification of
Parkin #2 are ATGCTGCCTTTGAGTTTTATGCAAAGG
and CCCCTGTCGCTTAGCAACCACTTC. The PCR prod-
ucts were gel purified, subjected to restriction digestion with KpnI
and NheI, and subcloned into the multiple cloning site of the
promoterless pGL4.10 vector from Promega (Sunnyvale, CA)
upstream of a synthetic luciferase coding sequence. Site-directed
mutagenesis of the candidate NF-kB binding site (GGGGCATCC)
Parkin Regulated by Inflammation
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MA) using the pGL4-Parkin #1 plasmid as the template. The
forward and reverse primers used were CCACCATTTCTTTC-
TGCCGCTAGCACATGCTGCCTTTGAG and CTCAAAGG-
CAGCATGTGCTAGCGGCAGAAAGAAATGGTGG, with the
mutated nucleotides underlined. The pGL4-tk-Renilla luciferase
vector, in which Renilla luciferase is constitutively expressed under
thecontrolofthethymidinekinase(tk) promoter, was obtained from
Promega (pGL4.74). The integrity of each plasmid was confirmed
by DNA sequencing.
Transfection of Reporter Plasmids and Luciferase Assays
MN9D cells were plated in 24-well plates at a density of 8610
4
cells per well. The following day, the cells of each well were
transfected with 450 ng of the indicated reporter plasmid and
50 ng of the pGL4-tk-Renilla Luciferase plasmid using 1.5 mLo f
FuGene6 (Roche Applied Science, Indianapolis, IN). After 4–
6 hours, cells were switched to serum-free media. The following
day, cells were treated with either PBS (vehicle) or 10 ng/mL TNF
for 18 hours. At the end of the treatment period, firefly and
Renilla luciferase activities were measured using the Dual-Glo
Luciferase Assay System (Promega) according to the manufactur-
er’s instructions. The amount of firefly luciferase activity of the
transfected cells was normalized to Renilla luciferase activity. Data
are expressed as the relative luciferase activity compared to that of
vehicle-treated cells that were transfected with the corresponding
reporter plasmid (which is set at 100% for each reporter plasmid).
TNF treatment did not affect the Renilla luciferase activity of the
internal control plasmid or the low level firefly luciferase activity of
the empty pGL4 plasmid.
Multiplexed High-Sensitivity Immunoassays
Conditioned media from mixed glia cultures from P2-P4 mouse
pups were collected to measure the protein concentration of seven
inflammatory mediators (IFN-c, IL-1b, IL-6, IL-10, IL-12, KC/
CXCL1, and TNF) using a high-sensitivity multiplexed immuno-
assay per the manufacturer’s instructions (Meso-Scale Discovery)
as published previously [24].
Results
Parkin mRNA and protein levels in brain microglia and
peripheral macrophages are decreased by LPS and TNF
Previous work from our group demonstrated that Parkin-null
mice displayed increased vulnerability to degeneration of DA
neurons in the ventral midbrain substantia nigra pars compacta
(SNpc) induced by chronic systemic inflammation [17]. While the
mechanism(s) by which Parkin protects the nigrostriatal pathway
against chronic inflammatory stress remain unknown, these
observations support the existence of important interactions
between Parkin and inflammatory factor signaling during innate
immune system activation.
First, we investigated the extent to which Parkin is expressed in
microglia and macrophages, cells involved in innate immunity. We
found that Parkin mRNA and protein are detectable by real-time
PCR and immunoblotting techniques respectively, in BV2
microglia, primary microglia and peritoneal macrophages
(Figure 1). Next, we investigated the extent to which Parkin
levels are regulated by inflammatory factors. Based on reports that
rotenone, glutamate and kainic acid exposure increased Parkin
mRNA and protein levels in neuronal cells [14], we expected that
inflammatory stimuli would also increase Parkin expression in
microglia and macrophages. Surprisingly, immunoblot analyses of
Parkin protein showed that treatment of the BV2 microglial cell
line with 10 ng/mL LPS decreased Parkin levels by 50% from
resting levels after 24 hours and by 24% after 48 hours;
stimulation with 1 ug/mL LPS decreased Parkin levels by 74%
after 24 hours and by 85% after 48 hours (Figure 1A). We
confirmed these findings in primary microglia from wild type
mice (Figure 1B). To extend these findings, we measured
Parkin mRNA by real-time PCR and found that Parkin mRNA
levels were also repressed by 10 ng/mL LPS or 10 ng/mL TNF.
Lastly, we observed similar results in LPS-treated primary
macrophages, the systemic cellular counterpart of brain microg-
lia (Figure 1C). These data suggest that inflammatory mediators
may negatively regulate transcription of Parkin mRNA and the
transcriptional repression accounts for decreased Parkin protein
levels.
Next we investigated specificity of the LPS-induced downreg-
ulation by testing for the necessity of proteins involved in LPS
signal transduction. The LPS receptor Toll-like receptor-4 (TLR4)
and its co-receptor MD-2 must recruit the adaptor protein
MyD88 to the cell surface to propagate inflammatory signaling
[25]. We harvested macrophages from MyD88-null mice, which
lack LPS-induced cytokine production [26]. Unlike peritoneal
macrophages harvested from wild type mice, macrophages
isolated from MyD88-null mice do not display downregulation
of Parkin protein or mRNA when stimulated with LPS
(Figure 2A). Tumor necrosis factor (TNF) is a potent inflamma-
tory cytokine that elicits classic activation responses in a number
of immune cell types through NF-kB-dependent signaling. To
further investigate the extent to which Parkin expression is acutely
regulated by inflammatory factors, we measured Parkin expres-
sion in peritoneal macrophages harvested from TNF-null mice.
We observed greater than two-fold increases in basal levels of
Parkin protein and mRNA levels in macrophages harvested from
TNF-null mice compared to those harvested from wild type mice
(Figure 2B). Together, these findings indicate that LPS and TNF
negatively regulate Parkin expression in microglia and macro-
phages.
NF-kB pathway activation mediates downregulation of
Parkin expression in microglia by LPS
Nuclear Factor Kappa-B (NF-kB) is a signaling pathway that
regulates many important processes in innate immune cells [27].
In resting microglia, NF-kB is bound to IkB and remains primarily
in the cytoplasmic compartment; in activated cells IkBi s
phosphorylated by IkB kinase (IKK) and subsequently degraded
which releases NF-kB, allowing it to translocate to the nucleus to
activate transcription of target genes [28]. CDDO-Imidazole
(CDDO-Im), a synthetic triterpenoid derivative of oleanolic acid
blocks activation of NF-kB [29,30,31]. Therefore, we employed
CDDO-Im to test the hypothesis that Parkin expression is
mediated by NF-kB signaling. First, we measured the mRNA
levels of Parkin and TNF, a classic NF-kB target gene, in the
presence of various concentrations of CDDO-Im in resting BV2
cells. We found that CDDO-Im induced a dose-dependent
increase in Parkin mRNA and a concomitant decrease in TNF
mRNA as measured by real-time PCR (Figure 3A). Next, we
measured the kinetics of LPS-induced changes in Parkin and TNF
mRNA in BV2 cells. We found that LPS induced a rapid decrease
in Parkin mRNA (70% decrease from baseline at 12 hrs post
stimulation) and the expected transient increase in TNF mRNA)
(Figure 3B). To test the effects of NF-kB inhibition during LPS
stimulation, we pre-incubated BV2 microglia cells in DMSO
vehicle or 1 mM of CDDO-Im for 1 hour then measured changes
in Parkin and TNF mRNA levels after exposure to 12 hrs of 1 ug/
mL LPS. Inhibition of NF-kB by pre-treatment with CDDO-Im
Parkin Regulated by Inflammation
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TNF mRNA expression as expected (Figure 3C). Similar results
were observed in BV2 cells treated with either N-a-tosyl-L-lysine
chloromethyl ketone (TLCK), a proteasome inhibitor shown to
block NF-kB activation by suppressing IkB degradation in RAW
264.7 macrophages [32] (data not shown), or with SN50, a cell-
permeable peptide that inhibits translocation of the NF-kB active
complex into the nucleus [33] (data not shown). In summary,
genetic and pharmacological data support the involvement of NF-
kB activation in downregulation of microglial Parkin mRNA in
response to LPS.
The mouse parkin gene promoter contains an NF-kB
regulatory site
We hypothesized that if NF-kB was involved in the regulation of
Parkin expression, stimulation of neuronal cells with TNF should
also activate NF-kB signaling and result in downregulation of
Parkin mRNA expression. To test this directly, we treated neurally
differentiated ventral mesencephalon MN9D neuroblastoma cells
with 10 ng/mL TNF and harvested the cells for RNA extraction
after 6, 12 or 24 hours of stimulation. In agreement with results
obtained in TNF-treated microglia and macrophages, QPCR
analysis revealed that TNF treatment induced downregulation of
Parkin mRNA in primary dopaminergic neuroblastoma cells
(Figure 4A). Next, we determined whether NF-kB was directly
regulating Parkin expression at the promoter level. Examination of
the mouse parkin promoter revealed the presence of sequence
motifs found in NF-kB target genes. The sequence 59-
GGGRNNYYCC-39 where R is A or G and Y is C or T has
been proposed to be an NF-kB target gene consensus sequence
based on alignment of established NF-kB binding sites [34].
Sequence analysis of the mouse parkin gene, including 3.2 kb
Figure 1. Parkin protein and mRNA expression in brain microglia and peripheral macrophages is regulated by LPS and TNF. A, Parkin
levels in BV2 microglia cells (plated in 6-well plates at 0.5610
6 cells/well) were treated with LPS as indicated. B, Parkin levels in primary microglia
(plated in 24-well plates at 0.1610
6 cells/well) were treated with LPS or TNF as indicated for 24 hr. Protein levels measured by immunoblotting are
shown on the left; Parkin mRNA levels as measured by real-time PCR (QPCR) are shown on the right. C, Parkin levels in primary peritoneal
macrophages (plated in 6-well plates at 0.8610
6 cells/well) were treated with LPS or TNF as indicated. The values indicate relative levels of Parkin
protein compared with housekeeping gene GAPDH or a-tubulin. QPCR analysis was performed by two-way ANOVA followed by Tukey’s post hoc test,
*p ,0.05 compared to the unstimulated sample. Data are representative of two to three independent dissections and treatments.
doi:10.1371/journal.pone.0023660.g001
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sequence that closely resembles this consensus sequence. We
performed reporter assays to determine whether this site on the
parkin promoter was a regulatory element necessary for inhibiting
Parkin transcription. To this end we generated two reporter
plasmids in which the mouse parkin gene promoter was cloned
upstream of a luciferase-coding sequence in the promoterless
pGL4 vector, either including (pGL4-Parkin #1) or excluding
(pGL4-Parkin #2) the site of interest, (Figure 4B). To ensure high
transfection efficiency, we transfected these Luc-reporter plasmids
into MN9D dopaminergic neuroblastoma cells along with a
plasmid that constitutively expresses Renilla luciferase as an
internal control. The transfected cells were subsequently treated
with saline or 10 ng/mL TNF for 18 hours after which firefly and
Renilla luciferase activities were measured in a luminometer. We
found that TNF treatment resulted in a 65% decrease in luciferase
activity in MN9D cells transfected with the pGL4-Parkin #1
plasmid which contains the putative NF-kB binding site
(Figure 4C). In contrast, no change in luciferase activity was
observed in response to TNF treatment in MN9D cells transfected
with the pGL4-Parkin #2 plasmid (which lacks the putative NF-
kB binding site in the mouse parkin promoter). Site directed
mutagenesis of this sequence in the parkin gene promoter ablated
the TNF-dependent repression of luciferase activity driven by the
parkin promoter (pGL4-Parkin #1 NF-kB Mutant), supporting our
idea that Parkin expression is regulated at the transcriptional level
by NF-kB,. These reporter assay experiments reveal that the
promoter of the mouse parkin gene contains a functional NF-kB
binding site. Together with pharmacological studies, our findings
strongly suggest that Parkin expression is repressed at the
transcriptional level by NF-kB pathway activation in cells treated
with LPS or TNF.
Parkin expression levels in immune cells affect
inflammatory gene expression
To explore the extent to which repression of Parkin expression by
inflammatory stimuli alters cellular effector functions, we examined
the expression levels of inflammatory and antioxidant markers in
resting or activated peritoneal macrophages from wild type and
Parkin-null mice. Isolated peritoneal macrophages were treated
with 10 ng/mL LPS for 4 hours prior to RNA harvest for real time
PCR analyses. Activated macrophages from Parkin-null mice
expressed increased levels of TNF, IL-1b, and iNOS mRNA
compared to wild type macrophages (Figure 5A), but no difference
in levels of Nrf2, HO-1, and NQO1 (Figure 5B). We detected no
change in expression of TLR4 or TLR2 (data not shown). These
data suggest a novel role in which Parkin may limit expression of
inflammatory mediators in resting and activated innate immune
cells. Thus, downregulation of Parkin expression by NF- kB in LPS
or TNF-treated cells may be necessary to elicit the typical
increasedexpression of a subset of inflammatory genes in activated
cells; consistent with this idea is the exacerbated inflammatory
response of LPS treated macrophages from Parkin-null mice.
Discussion
Based on the results from genetic, biochemical and pharmaco-
logical studies presented here, we propose a working model
(Figure 6) by which LPS and TNF stimulate microglia and
macrophages by binding TLR4 and TNF receptors, respectively to
result in activation of NF-kB-dependent gene transcription in
activated cells. Activation of this important pathway transiently
decreases Parkin mRNA and protein levels in microglia and
macrophages, suggesting that dynamic regulation of Parkin levels
may subservean important roleofParkininthese celltypes that may
Figure 2. Parkin downregulation by LPS requires intact TLR4 signal transduction. A, Primary peritoneal macrophages isolated from adult
wild type or MyD88-null mice were plated in 6-well plates at 0.8610
6 cells/well) and treated as indicated. Protein levels measured by immunoblot are
shown on the left; Parkin mRNA levels measured by real-time PCR (QPCR) are shown on the right. B, Parkin levels in naı ¨ve (untreated) macrophages
harvested from TNF-null mice. The values indicate relative levels of Parkin protein compared with that of the housekeeping gene a-tubulin. QPCR
analysis was performed by two-way ANOVA followed by Tukey’s post hoc test, ** p,0.01 compared to wild type sample and ## p,0.01 compared
to the unstimulated sample. Data are representative of two independent dissections and treatments.
doi:10.1371/journal.pone.0023660.g002
Parkin Regulated by Inflammation
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23660include limiting expression of genes involved in inflammatory
responses, as suggested by our QPCR analyses. Microglia and
macrophages respond to external stimuli in order to perform their
immune surveillance role in the central nervous system (CNS) and
peripheral circulation, respectively and they activate the NF-kB
signaling pathway in response to LPS and TNF treatment [27,28].
AlthoughNF-kB activates the expression of manytargetgenes, ithas
alsobeen reported to repress gene transcription, including that of the
rat androgen receptor [35]. Moreover, the Drosophila melanogaster
homolog of NF-kB/Rel (dorsal), positively regulates some genes while
negatively regulating others during embryonic development [36].
dorsal is reported to act as a repressor when it associates with a
neighboring co-repressor. The LPS-induced repression of Parkin
expression may occur through a similar mechanism involving a co-
repressor. The identification of a putative NF-kB site in the mouse
parkin promoter is a novel observation, and to our knowledge this is
the first demonstration that Parkin transcription is repressed by
inflammatory stimuli in microglia, macrophages and neurally
differentiated dopaminergic neuroblastoma cells.
Importantly, our finding that LPS and TNF-dependent NF-kB
signaling, which serves to activate microglia, also represses Parkin
levels suggests a complex interaction between neuroinflammatory
signaling and Parkin. One possible result of this interaction is that
a transient decrease in Parkin levels may be necessary for normal
activation and proliferation of microglia and macrophages
following LPS or TNF stimulation. In support of this idea, Parkin
expression was found to be transcriptionally repressed in dividing
cells [16]. Although this instance of repression was mediated by N-
myc, this example demonstrates a cellular mechanism of Parkin
downregulation during cellular proliferation. A similar example of
regulation through repression occurs in apoptotic signaling
cascades when specific members of the inhibitor of apoptosis
Figure 3. TNF and LPS induce downregulation of Parkin in an NF-kB-dependent manner. A, BV2 cells were plated into 6-well plates at a
density of 0.5610
6 cells per well. Parkin and TNF mRNA expression was measured in BV2 cells following an overnight incubation with only the
synthetic triterpenoid CDDO-Im at the concentrations indicated or in the vehicle DMSO. B, Parkin and TNF mRNA expression was measured in BV2
cells after stimulation with LPS (1 ug/mL) for the times indicated. C, Inhibition of NF-kB pathway activation in BV2 microglia cells with the synthetic
triterpenoid CDDO-Im (1 mM in DMSO) or its vehicle during LPS stimulation ablated LPS-induced repression of Parkin mRNA and attenuated LPS
induction of TNF mRNA (positive control). One way ANOVA followed by Tukey’s post hoc test, columns with different letters are significantly different
from each other, p,0.05.
doi:10.1371/journal.pone.0023660.g003
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apoptotic signaling to proceed [37,38]. While it is possible that
dynamic changes in Parkin levels subserve an important and as yet
undefined role of Parkin in microglial activation, complete loss of
Parkin may contribute to dysregulated microglial responses in the
CNS. In support of this idea, our data that LPS-treated Parkin-null
macrophages displayed heightened inflammation-related gene
expression suggests potentially important functional consequences
as a result of complete loss of Parkin in monocytes. Conversely,
microglia or macrophages with atypically high levels of Parkin
(such as those from TNF-null mice) displayed blunted activation
responses, in agreement with studies that show macrophages from
TNF-null mice display weakened activation responses when
challenged with oxidative stress [39,40]. Lastly, Parkin-null mice
have been reported to display increased microglial proliferation
and activation in the CNS [41] and mitochondrial alterations in
glial cells have been associated with an inability to provide trophic
support to neuronal cultures [42].
The functional consequences of acute and chronic downregula-
tionofParkin levelsinmicrogliaandmacrophagesanditsimpact on
DA neurons will be addressed in future studies; however, several
important predictions can be made on the basis of our findings and
our model. O-glycosylated a-synuclein (aSp22) has been shown to
be a Parkinsubstrate [43] and one expected consequence of chronic
downregulation of Parkin levels is likely to be accumulation of
Parkin substrates. Consistent with this prediction is the observation
thattherateofclearanceofa-synuclein aggregatesinBV2microglia
is significantly reduced after treatment of the cells with LPS [44].
Although the mechanism by which LPS attenuated a-synuclein
clearance in activated microglia in those studies was not explored,
our findings suggest that downregulation of Parkin levels by LPS-
induced NF-kB signaling might in part account for the accumu-
lation of a-synuclein and perhaps other Parkin substrates; this
possibility will need to be tested directly. Another important
prediction based on our in vitro findings is that chronic neuroin-
flammation and persistent activation of NF-kB in the CNS during
CNS infection has the potential to elicit a sustained reduction in
Parkin levels, which could also lead to dysregulation of microglia
and a toxic microenvironment for DA neurons. Alternatively,
repeated exposure to environmental toxins and/or the aging
process itself, both of which are associated with chronic neuroin-
flammation in the CNS, may also result in sustained reductions of
Parkin levels in the CNS. All of these environmental triggers could
essentially phenocopy the effect of parkin loss, thereby increasing the
vulnerability to peripheral inflammation-induced nigral dopami-
nergicpathwaydegeneration [17] andmaypredisposeanindividual
to development of PD.
Given that loss of dopamine (DA)-producing neurons in the
substantia nigra pars compacta is the neuropathological hallmark of
PD, it is understandable that research in the field has focused on
Figure 5. Parkin expression levels in macrophages affect inflammatory gene expression. Peritoneal macrophages were isolated from 18-
month old wild type and Parkin-null mice. Cells were plated and treated with 10 ng/mL LPS for 4 hours after which RNA was collected and processed
for QPCR analysis to measure levels of inflammatory (A) and antioxidant genes (B). Two-way ANOVA with Bonferroni’s post doc analysis, #p,0.05
and ###p,0.001 compared to no LPS treatment, while **p,0.01 and ***p,0.001 compared to wild type.
doi:10.1371/journal.pone.0023660.g005
Figure 4. The mouse parkin promoter contains a putative NF-kB binding site. A, TNF induces downregulation of Parkin mRNA in MN9D
dopaminergic neuroblastomacells. Cells were plated at a density of 3610
5 cells per well in 6-well plates (3 wells per condition). Parkin mRNA
expression was measured in MN9D cells after stimulation with TNF (10 ng/mL) for the times indicated. One way ANOVA followed by Tukey’s post hoc
test, columns with different letters are significantly different from each other, p,0.05. B, Schematic of the luciferase reporter plasmids driven by the
mouse parkin promoter, either including (#1) or excluding (#2) the putative NF-kB binding site. C, MN9D dopaminergic cells were plated at a density
of 8610
4 cell/well in 24-well plates (3 wells per condition) and transfected with the pGL4-Parkin reporter plasmids (#1, #2o r#1 mutant) and Renilla
luciferase plasmid. Firefly and Renilla luciferase activities were measured in a luminometer after an overnight treatment of 10 ng/mL TNF. Firefly
luciferase activity was normalized to internal control Renilla luciferase activity. Data are expressed as the relative luciferase activity compared to that
of vehicle-treated cells that were transfected with the corresponding reporter plasmid (which is set at 100% for each reporter plasmid). ANOVA
followed by Tukey’s post hoc test, * p,0.05. Data are representative of two independent transfections.
doi:10.1371/journal.pone.0023660.g004
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like pathology. However, recent studies suggest the exciting
possibilities that genes that influence the risk for development of
PD may have important roles in glial cells, and are involved in
innate immune function that determine how brain immune
surveillance cells respond to insult. Nurr1, a transcription factor
involved in the development and maintenance of DA neurons [45],
was recently reported to be a critical regulator of cytokine
expression in microglia and astrocytes. Elegant studies demonstrat-
ed that reduction in Nurr1 expression resulted in excess cytokine
production (includingTNF) thatled todeathofDAneuronsinLPS-
treated mice [46]. These unexpected findings underscore two
important ideas: the glial microenvironment surrounding DA
neurons is a critical determinant of neuronal health and survival;
and functions of ubiquitously expressed genes initially thought to be
important only in neurons may also have important roles in glial
cells and are likely to be dynamically regulated. In addition, genes
involved in histocompatibility and immunocompetence have been
identified as risk loci for PD in recent genome-wide association
studies (GWAS) [47]. Taken together, these exciting findings
provide compelling rationale to seek a deeper understanding of how
inflammatory signaling and innate immune processes influence the
functional outcome of neuron-glia interactions and contribute to or
protect against development of PD, the second most common
neurodegenerative disease in the U.S.
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